Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Monday, November 02, 2020
AB2 Bio and WuXi Biologics have entered into a collaboration to set-up and accelerate commercial-scale manufacturing of Tadekinig alfa, AB2 Bio’s novel recombinant IL-18 binding protein.
read more
Abarca has signed a value-based reimbursement contract with Biogen for select products in Biogen's leading multiple sclerosis portfolio.
read more
Thursday, February 02, 2012
ABB, the leading power and automation technology group, announces the introduction of the new MB-Rx in-situ Reaction Monitor for research laboratories and pilot plants in the chemical, petrochemical, pharmaceutical and biopharmaceutical industries.
read more
Tuesday, September 11, 2012
Abbott continues to expand contract manufacturing capabilities of its multi-product potent facility through the recent installment of a new roller compactor.
read more
Tuesday, December 18, 2012
Abbott Laboratories continues to advance its contract pharmaceutical manufacturing capabilities to meet the life science industry's expanding need for more efficient services for solid-dose potent and cytotoxic products.
read more
Abbott announced the FDA has issued Emergency Use Authorization for the company's molecular test for novel coronavirus.
read more
Wednesday, March 21, 2012
ABBOTT PARK, Ill., March 21, 2012 -- Abbott (NYSE: ABT) today announced that AbbVie [pronounced Abb-vee] will be the name of the new, independent research-based pharmaceutical company it expects to launch by the end of 2012.
read more
AbbVie and Alvine Pharmaceuticals, a leader in celiac disease therapeutics development, announced today that they have entered into a global collaboration to develop a novel oral treatment for patients with celiac disease, currently in Phase 2 ...
read more
Friday, November 30, 2018
AbbVie announced patent license agreements with Pfizer over its proposed biosimilar adalimumab product.
read more
Friday, November 09, 2018
AbbVie announced patent license agreements with Momenta over its proposed biosimilar adalimumab product.
read more
AbbVie (NYSE: ABBV) has named Michael Severino, M.D. its new Executive Vice President, Research and Development (R&D) and Chief Scientific Officer. Dr. Severino's track record of innovation within the biotech industry aligns with AbbVie's vision as ...
read more
Thursday, September 17, 2015
AbbVie in cooperation with Neurocrine Biosciences, Inc. has announced the completion of a Phase 2b clinical trial evaluating the safety and efficacy of elagolix alone or in combination with add-back therapy compared to placebo
read more
Thursday, January 03, 2013
AbbVie today marks its launch as an independent biopharmaceutical company, with employees from more than 40 countries and patients joining AbbVie leaders as they ring the first opening bell of 2013 at the New York Stock Exchange.
read more
Abbvie has completed its $21B buyout of Pharmacyclics.
read more
Abbvie has released details of the stock and cash breakdown of its previously announced $21B buyout of Pharmacyclics.
read more